Since the early 1980s, the U.S. Food and Drug Administration (FDA) has been interested in the individualization of therapy, that is, determining whether and how treatment should be modified for various demographic groups within the population. After several years of discussion, a guideline was published on the study of drugs in the elderly (1), and later a similar guideline on the study and evaluation of gender differences in the clinical evaluation of drugs was published (2) . Both 
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In addition to stressing the need to include a broad population in clinical trials and to analyze different gender and age groups for safety and efficacy responses, the two guidelines placed strong emphasis on the need to identify pharmacokinetic (PK) differences between groups (differences in the blood concentrations of a drug after similar doses). These differences are common and an important cause of different responses, and they are relatively easy to detect compared with pharmacodynamic differences among groups (different responses to the same blood concentrations). One way to identify PK differences is to do separate studies in each group of interest, for example, in women, men, elderly individuals, and people with renal failure. As an alternative to numerous trials, both guidelines also suggested the use of a PK screen, a method of searching for PK differences by examining steady-state blood concentrations of drugs in most participants in clinical trials. The PK screen, by examining a large number of individuals, is a means of detecting, inexpensively, a wide range of PK differences due to demographic and other influences, such as metabolic or excretory differences. The guidelines also recommended additional small studies of particu- (12) . Others, however, presumed that FDA was insisting that an NDA database be increased to provide separate answers to all questions for both sexes (13) . Moreover, although the guideline described what information was needed in a premarketing application, it left to sponsors the choice of how and when to obtain these data. This (9) found that the data on fewer than half of the drugs were analyzed for gender-related differences in drug response. Because (17) .
Since 1993 the FDA has stated and instructed sponsors that without these analyses or an agreement to conduct them promptly, the review of new marketing applications will not be initiated.
Perhaps the most controversial aspect of the FDA's changes was the withdrawal of the 1977 ban on the inclusion of women of childbearing potential in phase 1 and 2 trials and our urging that women be included. Concerns have been expressed about potential liability in the event of a fetal abnormality, especially if women are allowed to participate in clinical trials before the completion of reproductive toxicology studies, as allowed under FDA's new policy. It has also been argued that recommendations in the document with regard to contraception were incompletely developed (18) .
In its 1993 gender guideline, FDA did not abrogate its responsibility to the fetus, nor did it specify what the community must do. Rather, the agency withdrew a virtual federal ban on the inclusion of women in early studies and entrusted decisions about what to do to internal review boards, patients, and their physicians. This is not to say that the agency has no view on the matter. The FDA believes that the possibility of fetal exposure can be minimized by appropriate contraception, laboratory test-ing, and behavior. It is expected that study participants will be counseled about the importance of preventing pregnancy during a clinical trial. It is also expected that laboratory screening for pregnancy will be conducted before and at appropriate intervals during the study. As more preclinical information becomes available, it is expected that the sponsor and investigator will provide the relevant information to the study participant. Nonetheless, in so sensitive an area strong, diverse opinions will lead to further debate about differences in practice. In (2) and in a few large-scale heart trials, principally, the Physicians' Health Study (3) 
